Depot formulation

Patent metadata

Field	Value
Publication number	US-11596597-B2
Application number	US-202117168714-A
Country	US
Kind code	B2
Filing date	Feb 5, 2021
Priority date	May 16, 2018
Publication date	Mar 7, 2023
Grant date	Mar 7, 2023

Abstract

A pharmaceutical long acting depot composition is provided as an aid to smoking cessation treatment. The formulation comprises a therapeutically effective amount of varenicline or its pharmaceutically acceptable derivative and pharmaceutically acceptable excipients. The process of preparation of the formulation is also provided.

First claim

We claim:

1. A pharmaceutical long-acting depot composition comprising varenicline, or a pharmaceutically acceptable derivative thereof, and one or more pharmaceutically acceptable excipients dispersed in biodegradable carrier, wherein after administration to a subject in need thereof, the composition delivers a therapeutic dose of varenicline for a period of at least one week.

2. The composition according to claim 1 , wherein the particle size (d 90 ) of varenicline in the composition is from about 20 microns to about 100 microns.

3. The composition according to claim 1 , wherein the particle size (d 90 ) of varenicline in the composition is from about 40 microns to about 80 microns.

4. The composition according to claim 1 , wherein the therapeutic dose is from about 0.05 mg to about 5 mg per day.

5. The composition according to claim 1 , wherein the biodegradable carrier is in the form of microspheres, implants, cubosomes, hexosomes, solutions, suspensions, microemulsions, in-situ gelling system, or a combination thereof.

6. The composition according to claim 5 , wherein the biodegradable carrier comprises polylactide (PLA), poly(lactic-co-glycolic acid) (PLGA) 75:25, PLGA 50:50, polycaprolactone (PCL), linear polyhydroxy alkanoate (PHA), polybutylene succinate (PBS), polybutylene succinate adipate (PBSA), polybutylene adipate (PBA), polybutylene adipate terephthalate (PBAT), polycarbonates, polyurethanes, ethylene-vinyl acetate (EVA), polyurethane, or combination thereof.

7. The composition according to claim 1 , wherein the one or more pharmaceutically acceptable excipients are selected from stabilizers, matrix forming agents, lipids, viscosity enhancing agents, preservatives, buffering agents, isotonizing agents, injection vehicles, and combinations thereof.

8. The composition according to claim 7 , wherein the stabilizer is selected from polyoxyethylene derivatives of sorbitan esters, lecithin, polyoxyethylene ethers, polyoxypropylene ethers, sodium deoxycholate, and combinations thereof.

9. The composition according to claim 7 , wherein the matrix forming agent is selected from polyethylene glycol, sodium carboxymethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxypropylethyl cellulose, hydroxypropylmethyl cellulose, polyethylene glycols, polyoxyethylene, polyoxy-propylene ethers, polyvinylpyrrolidone, and combinations thereof.

10. The composition according to claim 7 , wherein the lipid is selected from phosphatidylcholine, purified egg yolk lecithin, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, phosphatidylinositol, sphingomyelin, hydrogenated soy phosphatidylcholine, dimyristoylphosphatidylcholine, dimyristoylphosphatidylglycerol, 1,2-distearoyl-sn-glycero-3-phosphocholine sodium, dipalmitoylphosphatidylcholine, hydrogenated soya phosphatidyl choline, phosphatidyl-N-methylethanolamine, and combinations thereof.

11. The composition according to claim 7 , wherein the viscosity enhancing agent is selected from sorbitol, glycerin, propylene glycol, and combination thereof.

12. The composition according to claim 7 , wherein the preservative is selected from benzyl alcohol, benzyl benzoate, methyl paraben, propyl paraben benzoic acid, butylated hydroxyanisole, butylated hydroxytoluene, chlorbutol, a gallate, a hydroxybenzoate, EDTA, phenol, chlorocresol, metacresol, benzethonium chloride, myristyl-β-piccolinium chloride, phenylmercuric acetate, thimerosal, and combinations thereof.

13. The composition according to claim 7 , wherein the injection vehicle is selected from water for injection, glycerin vegetable oil, oleic acid, ethyl undecanoate, almond oil, coconut oil, olive oil, soybean oil, (purified) triglycerides, propylene glycol esters, ethyl oleate, linseed oil, sunflower oil, peanut oil, olive oil, wheat-germ oil and combinations thereof.

14. The composition according to claim 1 , wherein the composition is an aqueous suspension comprising varenicline, or a pharmaceutically acceptable derivative thereof, and one or more pharmaceutically acceptable excipients selected from CMC, polysorbate 80, benzyl alcohol, or a combination thereof.

15. The composition according to claim 1 , wherein the viscosity of the composition is below about 75 mPa*s.

16. The composition according to claim 1 , wherein the varenicline, or a pharmaceutically acceptable derivative thereof, is present in an amount from about 1% to about 50% w/v of the total composition.

17. The composition according to claim 1 , wherein the varenicline is present as the free base.

18. The composition according to claim 1 , having a pH from 7 to 7.5.

19. The composition according to claim 1 , wherein the composition is a water-in-oil water double emulsion.

20. The composition according to claim 1 , wherein the composition is an aqueous suspension.

Assignees

• Cipla Ltd

Inventors

• Malhotra Geena
• Singh Sarabjit

Classifications

• A61K47/34

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

• A61K9/1274

  Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases · CPC title

• A61K9/0024 Primary

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• A61K9/06

  Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title